

Notice of Allowability	Application No.	Applicant(s)	
	10/817,163	SORENSEN, KENT S.	
	Examiner	Art Unit	
	Chester T. Barry	1724	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to 9/22/06 response.
2. The allowed claim(s) is/are 1-33.
3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All
 - b) Some*
 - c) None
 of the:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No./Mail Date _____.
 - (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. Notice of References Cited (PTO-892)
2. Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date _____
4. Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. Notice of Informal Patent Application
6. Interview Summary (PTO-413),
Paper No./Mail Date _____.
7. Examiner's Amendment/Comment
8. Examiner's Statement of Reasons for Allowance
9. Other _____.

Art Unit: 1724

The rejection under Sec. 112 (2nd paragraph) based on "high viscosity" is withdrawn because USP 6806078 provides evidence¹ that the person having skill in this art would have a reasonable understanding of what applicant meant by "high viscosity."


CHESTER T. BARRY
PRIMARY EXAMINER
571-272-1152

¹ Newman writes: "Recent interest has developed in the use of materials that slowly biodegrade or slowly release organic matter into ground water over time. A commercial product marketed under the brand name of HRC (Hydrogen Release Compound) has been used at many sites to slowly release lactic acid. As described in U.S. Pat. No. 6,420,594 such compounds comprise esters of polylactic acid and polyols. The compound is relatively expensive (approximately \$6.00/pound) compared to common low molecular weight substrates such as sugars (approximately \$0.30/pound), but is designed to provide a steady supply of lactic acid to ground water for up to a year. Injection of HRC into soil or ground water often results in a limited treatment radius due to the small volume and high viscosity of the injected material. Although the longevity of the product is greatly improved over simple sugars or other low molecular weight substrates reinjection of the product on an annual basis makes this treatment cost prohibitive at many sites" (emphasis added)